Clinical Trial Update: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing thymoglobulin to alemtuzumab in patients undergoing allogeneic stem cell transplantation has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Lymphoproliferative Diseases
• Myelodysplastic Syndromes
• Myelofibrosis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Gruppo Italiano Trapianto di Midollo Osseo | Conditions: Acute Myeloblastic Leukemia, Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: COMPLETED